The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Siteman Cancer Center receives Merit Extension from NCI

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, has earned a Merit Extension Award from NCI. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

UCLA researchers receive $3.9M NCI grant to boost the effectiveness of cancer immunotherapy

Cristina Puig-Saus, an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine at UCLA and an investigator at the UCLA Health Jonsson Comprehensive Cancer Center, and her research team have received a five-year, $3.9 million grant from NCI to develop drug-based strategies that could enhance cancer immunotherapy for patients with melanoma and potentially other types of cancer. 
In Brief

Dana-Farber Department of Pathology receives $2.8M grant from NCI

Dana-Farber Cancer Institute’s Department of Pathology, in collaboration with Brigham and Women’s Hospital, has received renewed funding for the Ruth L. Kirschstein NRSA Institutional Research Training Grant from the NCI, providing resources for pathology residents, clinical fellows, and PhD-trained scientists pursuing research careers in cancer pathology.
PodcastThe Directors

The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions”

How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
By Paul Goldberg and Claire Marie Porter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account